Letters
Cytisine to stop smoking
The case for licensing cytosine now for smoking cessation is overwhelming
BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5736 (Published 25 September 2013) Cite this as: BMJ 2013;347:f5736
- John A Stapleton, reader in addictions statistical analyses1
- 1King’s College London, Institute of Psychiatry, London SE5 8AF, UK
- john.stapleton{at}kcl.ac.uk
Prochaska and colleagues’ excellent overview of cytisine in smoking cessation fails to highlight the compelling cost-benefit evidence on why this effective, safe, and inexpensive drug should be licensed immediately worldwide.1 This case has already been made,2 and readers interested in this drug and the inflexibility of Western regulatory systems are directed to this article. …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.